Skip to main content
SpringerLink
Log in

The Pharmacology of Lymphocytes

  • Book
  • © 1988

Overview

Editors:
  1. Michael A. Bray

    1. Research Department, CIBA-GEIGY AG, Basel, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. John Morley

    1. Pharmaceutical Division, Preclinical Research, SANDOZ Ltd., Basel, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 85)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (28 chapters)

  1. Front Matter

    Pages I-XXII
    Download chapter PDF

  2. Glossary of Common Immunological Terms

    1. Glossary of Common Immunological Terms

      • Michael A. Bray, John Morley
      Pages 1-8

  3. Part 1

    1. Front Matter

      Pages 9-9
      Download chapter PDF

    2. The Evolution, Ontogeny, and Physiologic Function of Lymphocytes

      • J. Klein
      Pages 11-36

    3. De Novo Expression of Receptors on T Cells

      • J. M. Williams, T. B. Strom
      Pages 37-52

    4. Membrane Events During Lymphocyte Activation

      • J. T. Ransom, J. C. Cambier
      Pages 53-82

    5. Intracellular Events During Lymphocyte Activation

      • R. G. Coffey
      Pages 83-138

  4. Part 2

    1. Front Matter

      Pages 139-139
      Download chapter PDF

    2. Generation and Measurement of Antibodies

      • H. F. J. Savelkoul, S. S. Pathak, N. R. Sabbele, R. Benner
      Pages 141-185

    3. Monoclonal Antibodies to Lymphocyte Surface Molecules as Probes for Lymphocyte Functions

      • M. A. Talle, G. Goldstein
      Pages 187-213

    4. Interleukin 1 Production from Various Cells and Measurement of its Multiple Biologic Activities

      • C. A. Dinarello
      Pages 215-234

    5. Production and Measurement of Interleukin 2 and Interleukin 3

      • B. M. Stadler, K. Hirai, J.-F. Gauchat
      Pages 235-253

    6. Production and Measurement of Interferons

      • S. S. Alkan
      Pages 255-274

    7. Factors Regulating IgE Synthesis

      • C. Gaveriaux, T. Payne, F. Loor
      Pages 275-290

    8. Generation, Biology, and Assay of Efferent Lymphokines

      • D. Gemsa
      Pages 291-318

    9. Lymphocyte Purification, Growth, Cloning and Functional Assays

      • M. J. H. Ratcliffe, J. R. Lamb
      Pages 319-343

    10. Screening Strategies for Detecting Immunotherapeutic Agents

      • S. C. Gilman, R. T. Maguire, A. J. Lewis
      Pages 345-360

  5. Part 3

    1. Front Matter

      Pages 361-361
      Download chapter PDF

    2. Selected Autacoids as Modulators of Lymphocyte Function

      • M. M. Khan, K. L. Melmon
      Pages 363-383

    3. Lipid Mediators and Lymphocyte Function

      • M. J. Parnham, W. Englberger
      Pages 385-414
Back to top

Keywords

About this book

"Immunopharmacology" , why not "pharmacoimmunology"? Professor H. O. Schild University College London, 1962 An intact immune response is essential for survival, as is evidenced by the various innate immune deficiency syndromes and by the emergence of the acquired immune deficiency syndrome (AIDS) as a pandemic during the last decade. Substances which stimulate the immune response might contribute to the therapy of AIDS and its precursor, AIDS-related syndrome, as well as of other clinical conditions in which immune responses can be diminished, such as carcinoma and infections. In other circumstances, an intact or heightened immune response may pose clinical problems; hence there is need to suppress, or diminish, components of the immune response. For instance, it is necessary to impair cellular immunity in order to ensure lasting acceptance of heterografts and it is already established that agents effective in transplantation are therapeutically effective in an range of autoimmune diseases. More recently, experimental studies have indicated that aberrant manifestations of humoral immunity, as in allergies, may also be amenable to pharmacological intervention.

Editors and Affiliations

  • Research Department, CIBA-GEIGY AG, Basel, Switzerland

    Michael A. Bray

  • Pharmaceutical Division, Preclinical Research, SANDOZ Ltd., Basel, Switzerland

    John Morley

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation